Zusammenfassung
Die globale Diabetesprävalenz liegt heute bei 246 Millionen Menschen. Hochrechnungen für das Jahr 2025 sagen 380 Millionen Diabetiker voraus. In Deutschland haben 7 bis 8% der Bevölkerung einen Diabetes. Allerdings geht man von einer hohen Dunkelziffer an unerkanntem Diabetes aus. Die tatsächliche Zahl dürfte in Deutschland bei 7 bis 8 Millionen Diabetikern liegen, was bedeutet, dass etwa jeder 10. Bundesbürger betroffen ist. In den vergangenen Jahren haben mehrere Studien gezeigt, dass eine Prävention des Typ-2-Diabetes möglich ist. Vor allem eine Lebensstilintervention erbrachte diesbezüglich die besten Erfolge. Es gibt sowohl Menschen, die gut auf eine Lebensstilintervention ansprechen, als auch Personen, die hiervon nur wenig profitieren. Die erste Gruppe kann man als „Responder“, letztere als „Non-Responder“ bezeichnen. Mittlerweile gibt es sowohl genetische als auch phänotypische Merkmale, die den Erfolg einer Lebensstilintervention vorhersagen. Somit wird eine individualisierte Prävention des Typ-2-Diabetes möglich.
Abstract
The global estimated prevalence of diabetes today is 246 million people. By 2025, the figure is expected to rise to 380 million. In Germany about 7 to 8% of the population is diagnosed with diabetes. However, there are a large proportion of people with unknown diabetes and the total number of subjects with diabetes is estimated at 7 to 8 million, indicating that every tenth individual is affected by the disease. Several recent studies unanimously revealed that it is possible to prevent type 2 diabetes. Particularly lifestyle intervention showed promising results. However, there is large variability in the effect of the intervention, and people with a good response (responders) and with a low response (non-responders) can be identified. Meanwhile, several genetic and phenotypic markers have been identified, which can help predict the success of the lifestyle intervention, allowing for a more effective individualized prevention of type 2 diabetes.
Literatur
King H, Aubert RE, Herman WH (1998) Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care Sep 21(9):1414–1431
Wild S, Roglic G, Green A et al (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27(5):1047–1053
Rathmann W, Haastert B, Icks A et al (2003) High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 46(2):182–189
Cowie CC, Rust KF, Byrd-Holt DD et al (2006) Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999–2002. Diabetes Care 29:1263–1268
Cowie CC, Rust KF, Ford ES et al (2008) A full accounting of diabetes and prediabetes in the U.S. population, 1988–1994 and 2005–2006. Diabetes Care (Epub ahead of print)
Centers for Disease Control and Prevention (2003) National diabetes fact sheet general information and national estimates on diabetes in the United States, 2003. Centers for Disease Control and Prevention, U.S. Department of Human Services, Atlanta, GA
Massi-Benedetti M (2002) CODE-2 Advisory Board. The cost of diabetes Type II in Europe: the CODE-2 Study. Diabetologia 45(7):S1–S4
Narayan KM, Boyle JP, Thompson TJ et al (2003) Lifetime risk for diabetes mellitus in the United States. JAMA 290(14):1884–1890
Yoon KH, Lee JH, Kim JW et al (2006) Epidemic obesity and type 2 diabetes in Asia. Lancet 368(9548):1681–1688
Mokdad AH, Bowman BA, Ford ES et al (2001) The continuing epidemics of obesity and diabetes in the United States. JAMA 286(10):1195–1200
Tuomilehto J, Lindstrom J, Eriksson JG et al (2001) Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344:1343–1350
Knowler WC, Barrett-Connor E et al (2002) Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403
Pan XR, Li GW, Hu YH et al (1997) Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 20:537–544
Ramachandran A, Snehalatha C, Mary S et al (2006) The Indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia 49(2):289–297
Lindström J, Ilanne-Parikka P, Peltonen M et al (2006) Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 368(9548):1673–1679
Uusitupa M, Lindi V, Louheranta A et al (2003) Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes 52(10):2528–2532
Freeman DJ, Norrie J, Sattar N et al (2001) Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation 103(3):357–362
Chiasson JL, Brindisi MC, Rabasa-Lhoret R (2005) The prevention of type 2 diabetes: what is the evidence? Minerva Endocrinol 30(3):179–191
Buchanan TA, Xiang AH, Peters RK et al (2002) Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51(9):2796–2803
Gerstein HC, Yusuf S, Bosch J et al (2006) DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication Trial Investigators, effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368(9541):1096–1105
Chiasson JL, Josse RG, Gomis R et al (2002) Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359(9323):2072–2077
Torgerson JS, Hauptman J, Boldrin MN, Sjöström L (2004) XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 27(1):155–161
Kitabchi AE, Temprosa M, Knowler WC et al (2005) The diabetes prevention program research group. Role of insulin secretion and sensitivity in the evolution of type 2 diabetes in the diabetes prevention program: effects of lifestyle intervention and metformin. Diabetes 54(8):2404–2414
Lindi VI, Uusitupa MI, Lindström J, Finnish Diabetes Prevention Study et al (2002) Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes 51(8):2581–2586
Kubaszek A, Pihlajamäki J, Komarovski V, Finnish Diabetes Prevention Study et al (2003) Promoter polymorphisms of the TNF-alpha (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes: the Finnish Diabetes Prevention Study. Diabetes 52(7):1872–1876
Todorova B, Kubaszek A, Pihlajamäki J, Finnish Diabetes Prevention Study et al (2004) The G-250A promoter polymorphism of the hepatic lipase gene predicts the conversion from impaired glucose tolerance to type 2 diabetes mellitus: the Finnish Diabetes Prevention Study. J Clin Endocrinol Metab 89(5):2019–2023
Mager U, Lindi V, Lindström J, Finnish Diabetes Prevention Study Group et al (2006) Association of the Leu72Met polymorphism of the ghrelin gene with the risk of Type 2 diabetes in subjects with impaired glucose tolerance in the Finnish Diabetes Prevention Study. Diabet Med 23(6):685–689
Lindström J, Louheranta A, Mannelin M, Finnish Diabetes Prevention Study Group et al (2003) The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabetes Care 26(12):3230–3236
Herder C, Peltonen M, Koenig W et al (2006) Systemic immune mediators and lifestyle changes in the prevention of type 2 diabetes: results from the Finnish Diabetes Prevention Study. Diabetes 55(8):2340–2346
Florez JC, Jablonski KA, McAteer J, Diabetes Prevention Program Research Group et al (2008) Testing of diabetes-associated WFS1 polymorphisms in the Diabetes Prevention Program. Diabetologia 51(3):451–457
Stefan N, Kantartzis K, Häring HU (2008) Causes and metabolic consequences of Fatty liver. Endocr Rev 29(7):939–960
Stefan N, Machicao F, Staiger H et al (2005) Polymorphisms in the adiponectin receptor 1 Gene are associated with insulin resistance and high liver fat. Diabetologia 48(11):2282–2291
Stefan N, Kantartzis K, Machann J et al (2008) Identification and characterization of metabolically benign obesity in humans. Arch Intern Med 168(15):1609–1616
Stefan N, Thamer C, Staiger H et al (2007) Genetic variations in PPARD and PPARGC1A determine mitochondrial function and predict changes in aerobic physical fitness and insulin sensitivity during lifestyle intervention. J Clin Endocrinol Metab 92(5):1827–1833
Weyrich P, Machicao F, Reinhardt J et al (2008) SIRT1 genetic variants associate with the metabolic response of Caucasians to a controlled lifestyle intervention – the TULIP Study. BMC Med Genet 9:100
Weyrich P, Stefan N, Haring HU et al (2007) Effect of genotype on success of lifestyle intervention in subjects at risk for type 2 diabetes. J Mol Med 85(2):107–117
Frayling TM (2007) Genome-wide association studies provide new insights into type 2 diabetes aetiology. Nat Rev Genet 8(9):657–662
Florez JC, Jablonski KA, Bayley N, Diabetes Prevention Program Research Group et al (2006) TCF7L2 polymorphisms and progression to diabetes in the Diabetes Prevention Program. N Engl J Med 355(3):241–250
Lyssenko V, Jonsson A, Almgren P et al (2008) Clinical risk factors, DNA variants, and the development of type 2 diabetes. N Engl J Med 359(21):2220–2232
Kantartzis K, Thamer C, Peter A et al (2008) High cardiorespiratory fitness is an independent predictor of the reduction in liver fat during a lifestyle intervention in non-alcoholic fatty liver disease. Gut (Epub ahead of print)
Thamer C, Machann J, Stefan N et al (2007) High visceral adipose tissue mass and high liver fat content are associated with resistance to lifestyle intervention. Obesity (Silver Spring) 15(2):531–538
Auberger P, Falquerho L, Contreres JO et al (1989) Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 58:631–640
Stefan N, Hennige AM, Staiger H et al (2006) Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care 29:853–857
Hennige AM, Staiger H, Wicke C et al (2008) Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS ONE 3(3):e1765
Ix JH, Shlipak MG, Brandenburg VM ET AL (2006) Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation 113(14):1760–1767
Stefan N, Fritsche A, Weikert C et al (2008) Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 57(10):2762–2767
Stefan N, Häring HU, Schulze MB (2008) Association of fetuin-A level and diabetes risk. JAMA 300(19):2247
Weikert C, Stefan N, Schulze MB et al (2008) Plasma fetuin-a levels and the risk of myocardial infarction and ischemic stroke. Circulation 118(24):2555–25562
Schulze MB, Hoffmann K, Boeing H et al (2007) An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. Diabetes Care 30(3):510–515
Rathmann W, Martin S, Haastert B et al (2005) Performance of screening questionnaires and risk scores for undiagnosed diabetes: the KORA Survey 2000. Arch Intern Med 165(4):436–4341
Rosenzweig JL, Ferrannini E, Grundy SM, Endocrine Society et al (2008) Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93(10):3671–3689
Danksagung
PD Dr. med. Norbert Stefan wird durch ein Heisenberg-Stipendium der Deutschen Forschungsgemeinschaft (STE 1096/1-1) unterstützt.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stefan, N., Fritsche, A. & Häring, HU. Individualisierte Prävention des Typ-2-Diabetes. Bundesgesundheitsbl. 52, 677–682 (2009). https://doi.org/10.1007/s00103-009-0868-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00103-009-0868-7